Pricing Log in Create free account

Aceragen, Inc. (ACGN) vs Neuphoria Therapeutics Inc. (NEUP)

Aceragen, Inc. and Neuphoria Therapeutics Inc. are both Biotechnology companies. Aceragen, Inc. and Neuphoria Therapeutics Inc. are of similar size ($17.9M and $17.1M). Neuphoria Therapeutics Inc. grew revenue faster over the last twelve months: 3,535.1% against 1,226.3%. Neuphoria Therapeutics Inc. has the higher net margin (0.00% vs −467.5%) and the lower return on invested capital (−232.7% vs −135.4%). Across the 17 metrics below, Neuphoria Therapeutics Inc. leads on 12 and Aceragen, Inc. on 5.

Valuation

Metric ACGN NEUP Biotechnology median
P/E n/m n/m 8.50
P/S 1.52 0.91 9.71
P/B 0.83 0.58 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.27 0.64
EV/Sales 4.09 (0.30) 9.21
Earnings yield (181.40%) (154.60%) (33.15%)
Free cash flow yield (250.88%) (85.14%) (25.50%)

Profitability

Metric ACGN NEUP Biotechnology median
Gross margin 83.46% 0.00% 65.16%
Operating margin (503.92%) 0.00% 0.00%
Net margin (467.53%) 0.00% 0.00%
Free cash flow margin (339.17%) 0.00% 0.00%
Return on equity (169.66%) (61.70%) (56.36%)
Return on assets (75.58%) (46.95%) (48.04%)
Return on invested capital (135.35%) (232.67%) 0.00%

Growth

Metric ACGN NEUP Biotechnology median
Revenue growth (TTM) 1,226.28% 3,535.05% 6.02%
EPS growth (last fiscal year) (121.58%) (1,230.43%) 30.26%
Revenue growth, 5-year CAGR 81.19% 19.07% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ACGN NEUP Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 0.32 27.85 4.72
Net debt to EBITDA 0.43 1.26 0.96

Dividend

Metric ACGN NEUP Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ACGN NEUP Biotechnology median
Market cap 17.15m 17.91m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack